VIR
Vir Biotechnology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$11.39
−0.57%Year over year
Reported trailing growth
- Revenue
- +1495.9%
- EBITDA
- +56.9%
- EBIT
- +55.5%
- EPS
- +53.8%
- Free cash flow
- +28.9%
- Operating cash flow
- +26.8%
Forward estimates
Based on analyst estimates
- Revenue
- -82.3%
- EBITDA
- -72.4%
- EPS
- -38.2%
Three-year CAGR
- Revenue
- -65.1%
- EBITDA
- +16.3%
- EBIT
- +20.3%
- Net income
- +16.1%
- EPS
- +17.5%
- Free cash flow
- +12.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026